Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in Japan
Fluoroquinolone (FQ) and cephalosporin (CEP) resistance among Enterobacteriaceae has been increasingly reported. FQ resistance occurs primarily through mutations in DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE). CEP resistance in Enterobacteriaceae is mainly due to the production o...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-03-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844018337423 |
id |
doaj-3a9210d2ffb34e769a4af1a368a24d3b |
---|---|
record_format |
Article |
spelling |
doaj-3a9210d2ffb34e769a4af1a368a24d3b2020-11-25T02:07:05ZengElsevierHeliyon2405-84402019-03-0153e01291Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in JapanRyuichi Nakano0Akiyo Nakano1Michiko Abe2Noriyuki Nagano3Miwa Asahara4Taiji Furukawa5Yasuo Ono6Hisakazu Yano7Ryoichi Okamoto8Department of Microbiology and Infectious Diseases, Nara Medical University, Kashihara, Nara, Japan; Corresponding author.Department of Microbiology and Infectious Diseases, Nara Medical University, Kashihara, Nara, JapanDepartment of Medical Laboratory Sciences, Kitasato University School of Allied Health Sciences, Sagamihara, Kanagawa, JapanDepartment of Health and Medical Sciences, Shinshu University, Graduate School of Medicine, Matsumoto, Nagano, JapanDepartment of Central Clinical Laboratory, Teikyo University Hospital, Itabashi-Ku, Tokyo, JapanDepartment of Central Clinical Laboratory, Teikyo University Hospital, Itabashi-Ku, Tokyo, JapanDepartment of Microbiology and Immunology, Teikyo University School of Medicine, Itabashi-Ku, Tokyo, JapanDepartment of Microbiology and Infectious Diseases, Nara Medical University, Kashihara, Nara, JapanDepartment of Microbiology, Kitasato University School of Medicine, Sagamihara, Kanagawa, JapanFluoroquinolone (FQ) and cephalosporin (CEP) resistance among Enterobacteriaceae has been increasingly reported. FQ resistance occurs primarily through mutations in DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE). CEP resistance in Enterobacteriaceae is mainly due to the production of CTX-M type extended-spectrum β-lactamases. Although prevalence and mechanisms of FQ and CEP resistance in Enterobacteriaceae such as Escherichia coli have been well studied, little is known about Proteus mirabilis in Japan. In this study, we assessed the prevalence and mechanism of FQ resistance in Japanese clinical isolates of P. mirabilis. We collected 5845 P. mirabilis isolates from eight hospitals between 2000 and 2013. Prevalence of FQ resistance was calculated as the annual average percentage of all P. mirabilis isolates. We selected 50 isolates exhibiting susceptibility, intermediate resistance, or resistance to levofloxacin (LVX) and identified amino acid substitutions in GyrA, GyrB, ParC, and ParE. The prevalence of FQ-resistant P. mirabilis gradually increased from 2001 to 2004, reaching 16.6% in 2005, and has remained relatively high (13.3–17.5%) since then. Low-level LVX-resistant strains (MIC, 8–16 mg/L) showed significant changes in GyrB (S464Y or -I, or E466D). High-level LVX-resistant strains (MIC, 32–128 mg/L) displayed significant changes in GyrA (E87K) and ParE (D420N). The highest-level LVX-resistant strains (MIC, ≥ 256 mg/L) presented significant changes in GyrA (E87K or -G), GyrB (S464I or -F), and ParE (D420N). Our findings suggest that substitutions in GyrA (E87) and ParE (D420) have played an important role in the emergence of high-level LVX-resistant P. mirabilis isolates (MIC, ≥ 32 mg/L) in Japan.http://www.sciencedirect.com/science/article/pii/S2405844018337423MicrobiologyEpidemiology |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ryuichi Nakano Akiyo Nakano Michiko Abe Noriyuki Nagano Miwa Asahara Taiji Furukawa Yasuo Ono Hisakazu Yano Ryoichi Okamoto |
spellingShingle |
Ryuichi Nakano Akiyo Nakano Michiko Abe Noriyuki Nagano Miwa Asahara Taiji Furukawa Yasuo Ono Hisakazu Yano Ryoichi Okamoto Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in Japan Heliyon Microbiology Epidemiology |
author_facet |
Ryuichi Nakano Akiyo Nakano Michiko Abe Noriyuki Nagano Miwa Asahara Taiji Furukawa Yasuo Ono Hisakazu Yano Ryoichi Okamoto |
author_sort |
Ryuichi Nakano |
title |
Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in Japan |
title_short |
Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in Japan |
title_full |
Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in Japan |
title_fullStr |
Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in Japan |
title_full_unstemmed |
Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in Japan |
title_sort |
prevalence and mechanism of fluoroquinolone resistance in clinical isolates of proteus mirabilis in japan |
publisher |
Elsevier |
series |
Heliyon |
issn |
2405-8440 |
publishDate |
2019-03-01 |
description |
Fluoroquinolone (FQ) and cephalosporin (CEP) resistance among Enterobacteriaceae has been increasingly reported. FQ resistance occurs primarily through mutations in DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE). CEP resistance in Enterobacteriaceae is mainly due to the production of CTX-M type extended-spectrum β-lactamases. Although prevalence and mechanisms of FQ and CEP resistance in Enterobacteriaceae such as Escherichia coli have been well studied, little is known about Proteus mirabilis in Japan. In this study, we assessed the prevalence and mechanism of FQ resistance in Japanese clinical isolates of P. mirabilis. We collected 5845 P. mirabilis isolates from eight hospitals between 2000 and 2013. Prevalence of FQ resistance was calculated as the annual average percentage of all P. mirabilis isolates. We selected 50 isolates exhibiting susceptibility, intermediate resistance, or resistance to levofloxacin (LVX) and identified amino acid substitutions in GyrA, GyrB, ParC, and ParE. The prevalence of FQ-resistant P. mirabilis gradually increased from 2001 to 2004, reaching 16.6% in 2005, and has remained relatively high (13.3–17.5%) since then. Low-level LVX-resistant strains (MIC, 8–16 mg/L) showed significant changes in GyrB (S464Y or -I, or E466D). High-level LVX-resistant strains (MIC, 32–128 mg/L) displayed significant changes in GyrA (E87K) and ParE (D420N). The highest-level LVX-resistant strains (MIC, ≥ 256 mg/L) presented significant changes in GyrA (E87K or -G), GyrB (S464I or -F), and ParE (D420N). Our findings suggest that substitutions in GyrA (E87) and ParE (D420) have played an important role in the emergence of high-level LVX-resistant P. mirabilis isolates (MIC, ≥ 32 mg/L) in Japan. |
topic |
Microbiology Epidemiology |
url |
http://www.sciencedirect.com/science/article/pii/S2405844018337423 |
work_keys_str_mv |
AT ryuichinakano prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan AT akiyonakano prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan AT michikoabe prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan AT noriyukinagano prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan AT miwaasahara prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan AT taijifurukawa prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan AT yasuoono prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan AT hisakazuyano prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan AT ryoichiokamoto prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan |
_version_ |
1724931201866661888 |